Allergy Therapeutics
Research Allergy Therapeutics (AGY) on Bullrun: market cap GBX 32.30B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGY
- ExchangeLSE
- CountryUnited Kingdom
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
- CurrencyGBX
- Market capGBX 32.30B
- Financial periodFY2025
- RevenueGBP 55.04M
- Revenue growth-0.3%
- Net income-GBP 40.13M
- Free cash flow-GBP 31.53M
- Gross margin53.2%
Valuation Snapshot
latest market cap is GBX 32.30B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 55.04M | -GBP 40.13M | -GBP 31.53M | 53.2% | -0.01 | GBP 12.59M | GBP 60.09M | -GBP 28.19M |
| FY2024 | GBP 55.20M | -GBP 38.62M | -GBP 35.54M | 53.9% | -0.01 | GBP 12.72M | GBP 30.99M | GBP 7.36M |
| FY2023 | GBP 59.59M | -GBP 43.07M | -GBP 33.55M | 55.8% | -0.08 | GBP 14.65M | GBP 35.99M | GBP 4.11M |
| FY2022 | GBP 72.77M | -GBP 13.78M | -GBP 17.06M | 68.0% | -0.02 | GBP 20.32M | GBP 10.53M | GBP 37.77M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-24 | GBX 32.30B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 GBX.
About Allergy Therapeutics
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Allergy Therapeutics's market cap?
Allergy Therapeutics's market capitalization is GBX 32.30B.
What does Allergy Therapeutics do?
Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus.